Clinical Significance of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography/computed Tomography in the Follow-up of Colorectal Cancer: Searching off Approaches Increasing Specificity for Detection of Recurrence
Overview
Affiliations
Background: Nearly 40% of colorectal cancer (CRC) recurs within 2 years after resection of primary tumor. Imaging with fluorine-18-fluorodeoxyglucose (F-FDG) positron emission tomography/computed tomography (PET/CT) is the most recent modality and often applied for the evaluation of metastatic spread during the follow-up period. Our goal was to study the diagnostic importance of F-FDG-PET/CT data of maximum standardized uptake value (SUVmax), total lesion glycolysis (TLG) and the difference of SUVmax on dual-time imaging in CRC.
Patients And Methods: We examined the SUVmax value of lesions on control or restaging F-FDG-PET/CT of 53 CRC patients. All lesions with increased SUVmax values were confirmed by colonoscopy or histopathology. We compared PET/CT results with conventional imaging modalities (CT, MRI) and tumor markers (carbohydrate antigen 19-9 [Ca 19-9], carcinoembryonic antigen [CEA]).
Results: Mean SUVmax was 6.9 ± 5.6 in benign group, 12.7 ± 6.1 in malignant group. Mean TLG values of malignant group and benign group were 401 and 148, respectively. F-FDG-PET/CT was truely positive in 48% of patients with normal Ca 19-9 or CEA levels and truely negative in 10% of cases with elevated Ca 19-9 or CEA. CT or MRI detected suspicious malignancy in 32% of the patients and F-FDG-PET/CT was truely negative in 35% of these cases. We found the most important and striking statistical difference of TLG value between the groups with benign and recurrent disease.
Conclusions: Although SUVmax is a strong metabolic parameter (p = 0.008), TLG seems to be the best predictor in recurrence of CRC (p = 0.001); both are increasing the specificity of F-FDG-PET/CT.
Mihailovic J, Roganovic J, Starcevic I, Nikolic I, Prvulovic Bunovic N, Nikin Z J Clin Med. 2024; 13(12).
PMID: 38930131 PMC: 11204678. DOI: 10.3390/jcm13123602.
Lu X, Wang G, Feng L, Kan Y, Wang W, Yang J Quant Imaging Med Surg. 2024; 14(1):462-475.
PMID: 38223114 PMC: 10784033. DOI: 10.21037/qims-23-966.
Milardovic R, Dzananovic L, Beslija S, Beslic N, Puhalovic A, Cavaljuga S Acta Inform Med. 2023; 31(2):115-120.
PMID: 37711491 PMC: 10498371. DOI: 10.5455/aim.2023.31.115-120.
Role of 18F-FDG PET/CT in the Follow-up of Colorectal Cancer.
Milardovic R, Beslic N, Sadija A, Ceric S, Bukvic M, Dzananovic L Acta Inform Med. 2020; 28(2):119-123.
PMID: 32742064 PMC: 7382771. DOI: 10.5455/aim.2020.28.119-123.